Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Published:2019-09 Issue:9 Volume:14 Page:1608-1618
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kim Youjin,Kim Chu Hyun,Lee Ho Yun,Lee Se-Hoon,Kim Hong Sook,Lee Sook,Cha Hongui,Hong Sungjun,Kim Kyunga,Seo Sang Won,Sun Jong-Mu,Ahn Myung-Ju,Ahn Jin Seok,Park Keunchil

Funder

AstraZeneca

Post-Genome Technology Development Program

Ministry of Trade, Industry and Energy

Korea Health Industry Development Institute

Ministry of Health and Welfare

National Research Foundation of Korea

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate;Kato;Clin Cancer Res,2017

4. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1;Champiat;Clin Cancer Res,2017

5. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma;Saada-Bouzid;Ann Oncol,2017

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors;Clinical and Translational Oncology;2024-09-03

2. Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients;Frontiers in Oncology;2024-08-01

3. Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy;Investigative Radiology;2024-07-17

4. A Review of Immunotherapy in Non-Small-Cell Lung Cancer;Current Oncology;2024-06-17

5. Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies;Journal for ImmunoTherapy of Cancer;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3